• Emergent BioSolutions Secures $17 Million Contract Modification for Oral Suspension TEMBEXA® (brincidofovir), a Smallpox Antiviral, and Strengthens Overall U.S. Supply Chain

    Source: Nasdaq GlobeNewswire / 15 Sep 2025 05:35:40   America/Los_Angeles

    N/A
Share on,